N = 910 subjects with navigation complete and tissue sample obtained | |
---|---|
Malignant | 45.8% (417/910) |
Lung cancer | 40.1% (365/910) |
Non-Small Cell Lung Cancer (NSCLC) | 36.4% (331/910) |
Adenocarcinoma | 23.5% (214/910) |
Squamous Carcinoma | 11.4% (104/910) |
Other NSCLC | 1.5% (14/910) |
Small Cell Carcinoma | 2.9% (26/910) |
Neuroendocrine Carcinoma | 1.1% (10/910) |
Metastatic Carcinoma of Extrathoracic Origin | 4.4% (40/910) |
Lymphoma | 0.2% (2/910) |
Malignant Cells (unable to characterize) | 0.9% (8/910) |
Other | 0.3% (3/910) |
Site-Reported Non-Malignant or Inconclusive Results | |
Non-Malignant | 40.9% (372/910) |
Normal Lung Tissue/Bronchial Epithelium | 10.4% (95/910) |
Benign Non-Specific | 21.9% (199/910) |
Benign Inflammation | 15.3% (139/910) |
Otherb | 6.7% (61/910) |
Infection | 2.9% (26/910) |
Bacterial | 1.8% (16/910) |
Fungal | 0.9% (8/910) |
Viral | 0.2% (2/910) |
Granuloma | 1.4% (13/910) |
Atypical Cells | 1.9% (17/910) |
Lymphocytes | 1.1% (10/910) |
Organizing Pneumonia | 0.8% (7/910) |
Interstitial Lung Disease | 0.4% (4/910) |
Otherc | 1.0% (9/910) |
Inconclusive | 13.3% (121/910) |